Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
hydroxyurea "medac" 500 mg kapsler, hårde
medac, gesellschaft für klinische spezialpräparate mbh - hydroxycarbamid - kapsler, hårde - 500 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
adakveo
novartis europharm limited - crizanlizumab - anæmi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
siklos
theravia - hydroxycarbamid - anæmi, sickle cell - antineoplastiske midler - siklos er indiceret til forebyggelse af tilbagevendende smertefulde vaso-okklusive kriser, herunder akut chest syndrom, pædiatriske og voksne patienter, der lider af symptomatisk og segl-celle syndrom.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
hydrea 500 mg kapsler, hårde
paranova danmark a/s - hydroxycarbamid - kapsler, hårde - 500 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
xromi
nova laboratories ireland limited - hydroxycarbamid - anæmi, sickle cell - antineoplastiske midler - forebyggelse af vaso-okklusive komplikationer af seglcelleanæmi hos patienter over 2 år.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
oribamide 500 mg kapsler, hårde
orifarm generics a/s - hydroxycarbamid - kapsler, hårde - 500 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruxolitinib (som phosphat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiske midler - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi er indiceret til behandling af voksne patienter med polycythaemia vera, som er resistente over for eller intolerante over for hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi er angivet som monoterapi hos voksne til behandling af polycythaemia vera uden symptomatisk splenomegali.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
calciumfolinat "fresenius kabi" 10 mg/ml injektions-/infusionsvæske, opløsning
fresenius kabi deutschland gmbh - calciumfolinat - injektions-/infusionsvæske, opløsning - 10 mg/ml